NCT03155984View on ClinicalTrials.gov

Optimizing HBV Management During Anti-CD20 Antibodies

CompletedOBSERVATIONAL
Enrollment

83

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

June 1, 2017

Study Completion Date

December 1, 2017

Conditions
Liver DysfunctionImmune SuppressionHepatitis B
Interventions
DRUG

Anti-CD20 antibody

All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies

Trial Locations (1)

Unknown

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT03155984 - Optimizing HBV Management During Anti-CD20 Antibodies | Biotech Hunter | Biotech Hunter